Caro J J, Getsios D, Raggio G, Caro G, Black L
Caro Research, Boston, Mass; Caro Research, Montreal, Quebec, Canada.
Headache. 2001 May;41(5):456-64. doi: 10.1046/j.1526-4610.2001.01083.x.
To evaluate the cost-effectiveness of naratriptan for the treatment of migraine in Canada.
The substantial disability brought on by migraine, coupled with the high prevalence of this disorder, leads to substantial costs. Naratriptan is a newly developed triptan shown to be effective in the treatment of migraine.
Monte Carlo modeling techniques were used to simulate the experience of Canadian migraineurs over the course of 1 year. Data from a multinational study comparing oral naratriptan 2.5 mg to customary therapies were used in the cost-effectiveness analysis.
Naratriptan leads to an annual reduction in symptom duration of 225 hours compared to customary therapy not including other triptans. Reductions in lost productivity yield savings of Can $390 (1998 Canadian dollars) relative to customary therapy, which exceed the increase in drug costs resulting in overall savings of Can $109 per year.
The use of naratriptan in the treatment of migraine is an economically attractive option, leading to savings in overall costs. Increases in drug costs seem acceptable in light of reductions in symptom duration.
评估那拉曲普坦在加拿大治疗偏头痛的成本效益。
偏头痛导致的严重残疾，加上这种疾病的高患病率，产生了巨大的成本。那拉曲普坦是一种新开发的曲坦类药物，已证明对治疗偏头痛有效。
采用蒙特卡洛建模技术模拟加拿大偏头痛患者一年中的经历。一项比较2.5毫克口服那拉曲普坦与传统疗法的跨国研究数据用于成本效益分析。
与不包括其他曲坦类药物的传统疗法相比，那拉曲普坦使症状持续时间每年减少225小时。相对于传统疗法，生产力损失的减少节省了390加元（1998年加拿大元），这超过了药物成本的增加，每年总体节省109加元。
使用那拉曲普坦治疗偏头痛是一个经济上有吸引力的选择，可节省总体成本。鉴于症状持续时间的减少，药物成本的增加似乎是可以接受的。
